Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between
this translated document and the Japanese original, the original shall prevail.

September 20, 2024
CompanyAnicom Holdings, Inc.
Representative Director
Nobuaki Komori(Securities Code: 8715 TSE PRIME)
Inquiries toNorihiko Sakurai
Corporate Planning Department,
General Manager

Monthly Management Parameters, August 2024

The following is a summary of the major targets set as the management targets in Anicom Group's pet insurance
business and new business initiatives aimed at realizing the vision of becoming a prevention-oriented company.

Monthly Management Parameters, FY2024 (From April 1, 2024 to March 31, 2025)
AprilMay

June

July

AugustSeptember

4,670JPYmn

4,932JPYmn

4,750JPYmn

4,708JPYmn

4,832JPYmn

JPYmn(4,346 JPYmn)(4,594 JPYmn)（4,386 JPYmn)（4,367 JPYmn)（4,486 JPYmn)（4,515 JPYmn)

1,199,358

1,206,083

1,213,737

1,220,965

1,228,626(1,119,862)(1,126,210)(1,132,856)(1,140,258)(1,147,355)(1,154,322)

88.2%

88.0%

88.0%

88.1%

87.9%%(88.3%)(87.8%)(88.3%)(88.3%)(88.1%)(88.2%)

Kenkatsu

18,886

21,37919,166

18,26820,018(gut microbiota testing)(18,514)(18,945)(17,822)(16,835)(17,833)

736

741

750

756

760

(647)

(654)

(661)

(667)

(675)

18

18

19

19

19

(11)

(11)

(11)

(11)

(13)

Net premiums written(previous year)

No. of policies in force(previous year)

Renewal rate
(previous year)

No. of applicants of Doubutsu(18,258)(previous year)

No. of PARM hospitals*1(previous year)

No. of patents held*2(previous year)

(683)

(13)

October

DecemberJanuary

February

MarchJPYmn

JPYmn

JPYmn

JPYmn

JPYmn

JPYmn

(4,544 JPYmn)(4,465 JPYmn)(4,564 JPYmn)(4,738 JPYmn)(4,533 JPYmn)(4,731 JPYmn)(1,160,624 )(1,166,524)(1,172,819)(1,180,363)(1,186,940)(1,193,560)

Net premiums written(previous year)

NovemberNo. of policies in force(previous year)

Renewal rate
(previous year)%%%%%%(88.1%)(88.4%)(88.4%)(88.2%)(88.4%)(88.4%)(19,039)(17,722)(18,017)(18,648)(18,394)(20,386)

(692)

(693)

(699)

(703)

(711)

(729)

(15)

(15)

(15)

(17)

(18)

(18)

No. of applicants of Doubutsu
Kenkatsu(gut microbiota testing)(previous year)

No. of PARM hospitals*1(previous year)

No. of patents held*2(previous year)*1 This is a key figure regarding the progress of the regenerative medicine business.
The "Research and Development Partnership for Animal Regenerative Medicine (PARM)" is a non-profit mutual benefit corporation. Its purpose isto take advantage of industry-government-academia collaboration in order to standardize each process of cell therapy services for domestic animals(dogs and cats) and achieve the practical application of a system that makes it possible for veterinarians at all kinds of medical facilities to provide
safe and effective cell therapy services.
*2 We disclose the figure as a key figure related to the promotion of BioInsurTech using big data, with the aim of realizing a prevention-oriented
company that prevents injuries and illnesses before they occur.
(Reference) “Monthly Management Parameters” will be disclosed after middle of each month, but it will be disclosed on the same day as thequarterly earnings announcement date for June, September, December, and March.